Control of blood glucose levels and development of diabetic microangiopathy: effect of glibornuride.
Genetically selected, sucrose-fed Cohen diabetic rats, aged 2 1/2 mo, were treated intragastrically with glibornuride, twice daily for 7 1/2 mo. The dose of 6 to 12.5 mg was adjusted according to the blood glucose level. Diabetic siblings with a similar metabolic derangement were used as a control group. Glibornuride treatment resulted in a significant reduction in blood glucose and an elevation in plasma insulin. A decreased incidence of diffuse glomerulosclerosis was noted in the treated group, in comparison with the control group (34.0 vs. 61.8%, P less than 0.02). The incidence of retinal lesions was also lower in the glibornuride-treated group (16.7 vs. 48.0%, P less than 0.02). Animals with diffuse glomerulosclerosis had significantly higher blood glucose and cholesterol levels and lower plasma insulin than did animals with normal kidneys.
D000783:Aneurysm / Q000473:pathology; D000818:Animals; D001786:Blood Glucose; D002784:Cholesterol / Q000097:blood; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy* / Q000473:pathology; D003925:Diabetic Angiopathies / Q000473:pathology*; D003928:Diabetic Nephropathies / Q000473:pathology*; D007328:Insulin / Q000097:blood; D008297:Male; D051381:Rats; D012161:Retinal Artery / Q000473:pathology; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
D001786:Blood Glucose; D007328:Insulin; D013453:Sulfonylurea Compounds; D014280:Triglycerides; D002784:Cholesterol